Delivery Order SPE2DB22D9239-SPE2DB25FDF71

Award Date 1/6/25
Potential Completion Date 1/28/25
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 4,565,134,451 vials of the cancer drug Kadcyla 100 mg by July 31, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows the agency to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $15,358.74 contract is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication, by January 14, 2025. This order is placed under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $20,519.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Kadcyla 160 mg vials, a specialized oncology medication, with a period of performance through November 19, 2024. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 100 mg vials of the oncology drug Kadcyla. The contract has a completion date of July 5, 2024 and uses a Firm Fixed Price pricing structure. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,798.90, is for the delivery of 100 mg vials of the drug Kadcyla. The delivery order is part of a larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, that allows the agency to issue orders for a comprehensive range of...
The Defense Logistics Agency (DLA) awarded a $5,731.36 firm fixed-price delivery order (SPE2DB21FD3SR) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of 160 mg vials of the oncology drug Kadcyla. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (SPE2DB20D9127) held by DMS Pharmaceutical Group with the DLA, which covers a wide range of branded and generic...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract, valued at $92,166.76, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. This contract is for the delivery of Kadcyla 160 mg vials and has an ultimate completion date of August 2, 2024. The contract is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued up to $499,999,999, which allows the DLA to issue delivery orders for a...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $26,654.84, is for the delivery of KADCYLA 160 MG vials. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which runs through December 31, 2025. The IDC...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $49,247.04 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 160 mg vials of the drug Kadcyla, with a completion date of January 17, 2025. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued at $499,999,999, which allows the DLA to issue firm fixed-price orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,327.42 contract is for the delivery of 160 mg vials of the oncology drug Kadcyla. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the agency to issue...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDF71
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,915.24, is for the delivery of 100 mg vials of the cancer drug Kadcyla. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 4/7/25, 9:46 AM